A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome

Autor:	Brandon S. Walker, Robert L. Schmidt, Edward R. Ashwood, Brian R. Jackson, Danielle Lagrave
Rok vydání:	2015
Předmět:	Oncology medicine.medical_specialty Down syndrome business.industry Cost effectiveness Obstetrics and Gynecology Cost-effectiveness analysis medicine.disease Prenatal screening Cell-free fetal DNA Internal medicine Immunology medicine Serum screening business Genetics (clinical)
Zdroj:	Prenatal Diagnosis. 35:440-446
ISSN:	0197-3851
Popis:	Objective The aim of this article is to determine the cost effectiveness of cell free DNA (cfDNA) as a replacement forintegrated screening using a societal cost perspective. Method This study used Monte-Carlo simulation with one-way and probabilistic sensitivity analysis. Results Cell free DNA is more effective and less costly than integrated screening. The incremental cost-effectivenessratio for cfDNA relative to the integrated test was $277955 per case detected (95th percent confidence interval $881882 to $532785). Conclusion Cell free DNA screening is a cost-effective replacement for maternal serum screening when the lifetimecosts of Down syndrome live births are considered. The adoption of cfDNA screening would save approximately$277955 for each additional case detected over integrated screening. © 2014 John Wiley & Sons, Ltd. Funding sources: NoneConflicts of interest: All of the authors are employees of ARUP laboratories, which provide a wide range of clinical laboratory tests including prenatal screening tests(both maternal serum screening and cfDNA).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c4988f3c7415a8ff12721f64b9ee339a https://doi.org/10.1002/pd.4511 Zobrazit plný text záznamu Plný text